AbbVie’s telisotuzumab dizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...

Researchers at ASCO provided a look at DB-1310 and iza-bren in genomically altered NSCLC, amid an overall survival miss for ...

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...

First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy ...

The primary endpoints of TROPION-Lung02 are dose-limiting toxicities and treatment-emergent adverse events. Secondary endpoints include ORR, DoR, PFS as assessed by investigator, overall survival, ...

Approximately 70% of breast cancers are HR-positive/HER2 negative. While activating ESR1 mutations are rare at the time of ...

Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line treatment.

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study ...

Rahway: Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, have announced that the Biologics ...

Leading international medical research company, MEDSIR announced today the positive results of the TUXEDO-3 trial at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. This phase II ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...